NCT03012100: Multi-epitope Folate Receptor Alpha Peptide Vaccine, Sargramostim, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer

NCT03012100
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Chemotherapy, Immunotherapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: No evidence of local recurrence or distant metastases after receiving treatment (e.g. chemotherapy, surgery, radiation)
https://ClinicalTrials.gov/show/NCT03012100

Comments are closed.

Up ↑